Black Diamond Therapeutics, Inc. SEC filings BDTX

Black Diamond Therapeutics, Inc. has 485 filings in SEC EDGAR's recent list, going back to Mar 28, 2017. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Black Diamond Therapeutics, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Mar 16, 2026 —
S-3 Shelf registration Nov 13, 2025 —
S-8 Employee stock plan registration Mar 6, 2025 —
S-8 Employee stock plan registration Mar 12, 2024 —
424B5 Prospectus supplement Jun 30, 2023 —
424B5 Prospectus supplement Jun 29, 2023 —
S-8 Employee stock plan registration Mar 9, 2023 —
S-3 Shelf registration Nov 14, 2022 —
S-8 Employee stock plan registration Mar 17, 2022 —
S-8 Employee stock plan registration Mar 25, 2021 —
S-3ASR Automatic shelf registration Feb 1, 2021 —
S-8 Employee stock plan registration Jan 30, 2020 —
424B4 Prospectus Jan 30, 2020 —
S-1MEF Filing Jan 29, 2020 —
S-1/A Amended registration statement Jan 21, 2020 —
S-1 Registration statement Jan 3, 2020 —

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BDTX (Nasdaq)
Fiscal year ends
December 31
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1701541
Former names
Aset Therapeutics, Inc. (until Jan 4, 2018)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.